Deciphera Pharmaceuticals, Inc. - a prominent biopharmaceutical firm - has been actively involved in the discovery, development, and commercialization of innovative medicines to enhance the quality of life for cancer patients across the globe, including the United States. The company's flagship drug candidate, QINLOCK, is currently used for the effective treatment of gastrointestinal stromal tumors (GIST) and has shown promising results in the INTRIGUE Phase 3 trials as a treatment for second-line GIST. In addition, Deciphera is also developing vimseltinib - an orally administered switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) to treat tenosynovial giant cell tumor (TGCT) - along with DCC-3116 for the treatment of RAS/RAF mutant cancers in combination with RTK/RAS/MAP kinase signaling pathway inhibition. Since its inception in 2003, Deciphera Pharmaceuticals, Inc. has remained headquartered in Waltham, Massachusetts, and has emerged as a crucial player in the fight against cancer.
Deciphera Pharmaceuticals's ticker is DCPH
The company's shares trade on the NASDAQ stock exchange
They are based in Waltham, Massachusetts
There are 201-500 employees working at Deciphera Pharmaceuticals
It is deciphera.com/who-we-are
Deciphera Pharmaceuticals is in the Healthcare sector
Deciphera Pharmaceuticals is in the Biotechnology industry
The following five companies are Deciphera Pharmaceuticals's industry peers: